Glenmark Pharmaceuticals Shares Close Higher On Positive Management Commentary
The management said fiscal 2026 would be a big year for the company in terms of overall growth.
Shares of Glenmark Pharmaceuticals surged on Monday on the back of positive commentary by management in the earnings call. The company is targeting a revenue of Rs 13,500–14,000 crore in the financial year 2025.
The company is expecting an Ebitda margin of 19% in comparison to 10% in the last fiscal. It is also expecting double-digit growth in net profit, according to the earnings call.
Glenmark has guided a research and development investment of 7–7.25% of the sales. The overall consolidated capital expenditure would be approximately Rs 700 crore.
The management said fiscal 2026 would be a big year for the company in terms of overall growth.
The company said that it is in talks with the US Food and Drug Administration for a meeting and re-inspection of its Monroe facility. The drug regulator received a warning letter last June.
Shares of the company were trading 8.49% higher at Rs 1,124 apiece on the NSE at 3.30 p.m., compared to a 0.11% decline in the benchmark Nifty.
The share price has risen 88% in the last 12 months. The relative strength index was at 70.
Six out of the 14 analysts tracking the company have a 'buy' rating on the stock, five recommend a 'hold' and three suggest a 'sell', according to Bloomberg data. The average of 12-month analyst price targets implies a potential downside of 10%.
